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Abstract 
Perivascular  epithelioid  cell  tumors
(PEComas)  are  a  rare  collection  of  tumors
arising in a wide array of anatomic locations
and characterized by a myomelanocytic pheno-
type.  PEComas  which  occur  in  non‐classic
anatomic distributions are known as perivas-
cular  epithelioid  cell  tumor‐not  otherwise
specified (PEComa‐NOS), and one of the most
common primary sites for PEComa‐NOS is the
uterus.  The  risk  of  aggressive  behavior  of
these tumors has been linked to a number of
factors evaluable on pathologic review follow-
ing initial surgical resection. We report a case
of PEComa‐NOS of the uterus with multiple
high‐risk  features,  including  frank  vascular
invasion, with no evidence of recurrent dis-
ease  18  months  following  initial  surgical
resection.
Introduction
Perivascular  epithelioid  cell  tumors
(PEComas)  are  a  collection  of  rare  tumors
defined by the World Health Organization as
mesenchymal  tumors  composed  of  histologi-
cally  and  immunohistochemically  distinctive
perivascular epithelioid cells.1 Bonetti et al.,
coined the term perivascular epithelioid cell
(PEC) for these cells in 1992 and proposed the
presence of this distinctive cell as a common
link between a number of rare disorders in dis-
parate  locations,  including  angiomyolipoma
(AML) of the kidney as well as clear cell sugar
tumors  (CCST)  and  lymphangiomyomatosis
(LAM) of the lung.2
Further descriptions of tumors in multiple
anatomic  locations  composed  primarily  of
these cells has led to them being designated
PEComas, as first suggested by Zamboni et al.
in  1996.3 These  tumors  are  notable  for  a
myomelanocytic  phenotype,  with  nearly  all
PEComas  being  immunoreactive  for  both
melanocytic  (HMB‐45  and/or  melan‐A)  and
smooth muscle (actin and/or desmin) mark-
ers. The PEComa family of tumors is now felt
to be comprised of AML, CCST, LAM and less
well‐characterized  PEComas  of  a  variety  of
other  anatomic  origins,  for  which  the  term
perivascular epithelioid cell tumor‐not other-
wise specified (PEComa‐NOS) has been pro-
posed.4
Multiple case reports and case series have
described  PEComa‐NOS  in  a  number  of
diverse  anatomic  locations  including  the
colon, pancreas, heart and breast.3,5‐9
One of the most common primary sites for
PEComa‐NOS  is  the  female  genitourinary
tract, and more specifically, the uterus,10 and
patients with PEComa‐NOS of the uterus have
a demonstrated a wide variety of clinical out-
comes.
Case Report
A  50  year  old  gravida  3,  para  3
African‐American female with a distant diag-
nosis of uterine fibroids presented to her local
emergency department with acute worsening
of  chronic  abdominal  pain  which  had  been
present for 4‐6 months. Her past medical his-
tory was otherwise unremarkable with no fea-
tures suggestive of tuberous sclerosis, and ini-
tial evaluation revealed hypotension and ane-
mia with a hematocrit of 32%. Physical exam
revealed  a  moderately  tender  abdomen  and
unremarkable pelvic exam.
Subsequent imaging in the form of a com-
puted tomography (CT) scan revealed a large
and very vascular pelvic mass with extension
into the lower and midabdomen…measuring
25 cm ﾥ 11 cm ﾥ 22 cm. Moderate intraperi-
toneal fluid, mesenteric fat stranding and an
intraluminal filling defect of the right ovarian
vein were also noted.
With a working diagnosis of bleeding uter-
ine myomata, she was taken to the operative
theater  the  following  day.  Upon  opening,
hemoperitoneum and a large, fungating, vas-
cular mass arising from the uterus and adher-
ent  to  the  overlying  omentum  were  noted.
During the dissection of the adherent omen-
tum from the underlying tumor, a number of
markedly dilated mesenteric veins were noted,
and one left parametrial vein was transected,
yielding  an  approximately  4‐5  cm  worm‐like
mass felt to be tumor thrombus.
Pathology review of the surgical specimens
revealed a multinodular 22ﾥ17ﾥ10.5 cm mass
arising from the superior aspect of the uterine
corpus  and  infiltrating  the  subersosa  and
>50% of the myometrium. On gross examina-
tion, the mass was described as having hemor-
rhagic, tan/yellow, softened cut surfaces with
multiple  finger‐like  projections  into  the
myometrium (Figure 1). The parametrial soft
tissue margins revealed residual disease, and
both ovaries contained discrete tumor nodules.
The mass extracted from the left parametri-
al vein was also consistent with tumor. One left
pelvic lymph node was sampled without evi-
dence of metastatic disease.
Microscopic review revealed predominantly
epithelioid  cells  with  a  clear  to  lightly
eosinophilic cytoplasm; in areas the neoplastic
cells showed granular cell change. Extensive
areas of hemorrhage, coagulative necrosis and
prominent vascular invasion were also noted;
the mitotic index was 2/50 high powered fields
(HPF) (Figure 2).
Extensive  pleomorphism  and  occasional
giant cells were noted with some cells contain-
ing intranuclear inclusions. No spindle cells
were seen and the vascular pattern was rela-
tively  inapparent.  The  neoplastic  cells  were
positive for HMB‐45, melan A, smooth muscle
actin,  desmin,  and  estrogen  receptor,  while
they were negative for S100, pankeratin, inhib-
in alpha and tyrosinase (Figure 3). Given the
myomelanocytic  phenotype,  a  diagnosis  of
PEComa was made. Given the size of the pri-
mary mass and the presence of multiple high
risk  features  as  proposed  by  Folpe,  et  al.,11
(Table 1) this was felt to represent a malignant
or high‐risk PEComa.
The patient made a full recovery, and CT of
the chest, abdomen and pelvis 5 weeks follow-
ing  surgery  revealed  a  small,  subsegmental
pulmonary  embolus  (PE),  multiple  bilateral
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sub‐cm  pulmonary  nodules  and  a  tubular
9.0ﾥ2.4 cm mass within the right gonadal vein
(Figure 4). The PE, small pulmonary nodules
and  likely  gonadal  vein  thrombus  all  raised
concern as potential sites of residual disease,
so a Positron Emission Tomography/Computed
Tomography  (PET/CT)  scan  was  performed.
This  demonstrated  mild,  indeterminate  FDG
uptake both within a mass located inside the
right gonadal vein as well as in the post‐oper-
ative field. No distant FDG uptake was noted.
After  a  lengthy  conversation  regarding  the
potential utility of surgical assessment of the
right gonadal vein and systemic therapy, the
patient opted not to pursue further diagnostic
evaluation or adjuvant therapy. She was start-
ed on systemic anticoagulation with warfarin
and active surveillance was undertaken in the
form of serial CT scans.
Over the course of the interim 18 months,
serial  CT  scans  have  demonstrated  initial
shrinkage followed by complete resolution of
both the right gonadal vein thrombus and the
subsegmental  PE.  The  multiple  small  pul-
monary nodules have been unchanged on seri-
al imaging exams and there has been no radi-
ologic evidence of local recurrence.
Given the lack of evidence for residual or
recurrent  malignancy,  her  warfarin  was  dis-
continued after a 6 month course of therapy
and  she  has  returned  to  an  active  lifestyle
without complaint.
Discussion
Given the rarity of PEComas and their rela-
tively  recent  description,  little  is  known  in
regards to risk factors for development of these
tumors, epidemiologic patterns of disease or
natural history following initial treatment. The
bulk of what is known has been gleaned from a
number of case reports and case series and
thus descriptive in nature. Series consistently
report a strong female predominance, with a
female‐male ratio as high as 9:1 noted in some
case series,11 likely at least in part to the large
number of cases originating from the female
genitourinary tract. Although the median age
at diagnosis is typically in middle age in most
series,10‐12 PEComa‐NOS has been diagnosed
in  patients  ranging  from  3  to  97  years  of
age.11,13
PEComas  have  an  unpredictable  biologic
behavior,  with  some  tumors  being  unre-
sectable or metastatic at the time of diagno-
sis,14,15a majority behaving in a benign fashion
and apparently curable with surgical resection
alone,  and  still  others  experiencing  relapse
after surgery, in some cases as long as 15 years
postoperatively.16 In an effort to better define
risk  factors  for  aggressive  behavior  and
relapse, Folpe, et al. proposed provisional risk
stratification  criteria  based  on  a  number  of
pathologic findings in 2005.11 When applying
these criteria to 59 cases reported in the liter-
ature at that time, 71% (12/17) patients whose
cases met the criteria for malignant disease
demonstrated malignant behavior, defined as
metastatic or recurrent disease. These criteria
have been widely adopted in an effort to pre-
dict the natural history of these rare tumors,
although they have not been validated, nor has
their use been uniformly linked to recommen-
dations for management at this point.
Given  the  fact  that  gynecologic  PEComas
are relatively common, a number of attempts
to provide useful risk stratification criteria for
this subset of patients have been undertaken
over  the  past  decade.  Fadare10 reviewed  41
reported cases of uterine PEComas and con-
cluded  that  a  high  mitotic  rate  (defined  as
>1/10  HPF)  and  presence  of  coagulative
necrosis were the best predictors of malignant
behavior in this subgroup of patients. Zekry, et
al.12 reviewed 53 cases of gynecologic (cervi-
cal, uterine and ovarian) PEComa and focused
on clinical rather than pathologic risk factors.
The only significant risk factors predicting a
poorer  prognosis  were  increasing  age,
metastatic  disease  at  presentation,  and
receipt  of  additional  therapy  (chemotherapy
and/or radiation therapy) as a part of a multi-
modality strategy including surgical resection.
The  authors  suggest  that  the  association
between poor prognosis and need for addition-
al therapy is likely attributable to the fact that
patients felt to be at higher risk for relapse
were more likely to receive additional therapy
as opposed to an intrinsic harm in undergoing
such treatment.
Surgery  remains  the  mainstay  of  therapy
when  possible  in  PEComas  of  nearly  every
anatomic  site.  Surgical  resection  of
oligometastatic disease has also been of ben-
efit, leading to long disease‐free intervals in a
number of cases of relapsed disease, especial-
Case Report
Figure  1.  Gross  surgical  specimen.  A)
Primary tumor measured 22ﾥ17ﾥ10.5 cm
mass described as a large, mulitnodular
infiltrating  mass;  B)  cut  surfaces  were
described  as  hemorrhagic,  tan/yellow,
softened surfaces; C) evidence of diffuse
invasion of vascular structures on gross
evaluation.
Figure 2. A) Uterine PEComa showing infiltrative growth into the myometrium; B) nests
of  perivascular  epithelioid  cells  clear  to  slightly  eosinophilic  cytoplasm,  moderate
nuclear variability and small nucleoli.[Rare Tumors 2012; 4:e14] [page 47]
ly in late relapses.14,17 Radiation therapy has
been utilized in a number of cases in both the
neoadjuvant  and  adjuvant  setting,  without
convincing results.11,14 Cytotoxic chemothera-
py has similarly been integrated into multi-
modality  therapy,  with  very  few  confirmed
responses.17,18 A newer approach utilized pri-
marily in the setting of recurrent or metastat-
ic disease has been targeted therapy, namely
mTOR inhibition.
The rationale behind mTOR inhibitor use in
these tumors lies in the fact that both classic
PEComas and PEComa‐NOS have been shown
to  frequently  harbor  mutations  in  the  TSC1
and/or TSC2 genes, which regulate cell prolif-
eration via the mTOR pathway.19,20 Initial trials
of these agents in the classic PEComas (AML,
LAM)  has  led  to  a  number  of  meaningful
responses,21,22 sparking  interest  in  their  use
for  metastatic  or  recurrent  PEComa‐NOS.  A
number of case reports of mTOR inhibition in
PEComa‐NOS have now been published, with
some  long  term  responses,16 although  these
responses have not been uniform.23
In conclusion, PEComa‐NOS remains a rare
diagnosis with a widely variant and difficult to
predict  natural  history.  This  report  demon-
strates that even with multiple high risk fea-
tures, patients can survive without recurrence
for relatively long periods, as our patient had
evidence  of  at  least  4  high  risk  criteria  on
pathologic review and is without evidence of
recurrence 18 months following surgical resec-
tion. Further investigation into potential pre-
dictors of poor prognosis must be undertaken
in an effort to further clarify risk of aggressive
behavior in patients with this diagnosis and,
eventually,  to  help  guide  management  deci-
sions. Given the often indolent biologic behav-
ior of this disease and reports of late recur-
rences as long as 15 years after initial surgical
resection,  continued  vigilance  will  be  of
utmost  importance  in  this  case,  especially
given the history of positive surgical margins.
Surgical resection of oligometastatic disease
and/or  mTOR  inhibition  would  likely  be  the
favored  interventions  should  recurrence  be
detected, based on emerging data on the role
of the mTOR pathway in the pathogenesis of
these tumors.
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